Results 81 to 90 of about 51,607 (296)

Cytarabine Induced Acute Cerebellar Syndrome during Hyper-CVAD Treatment for B-Cell Acute Lymphoblastic Leukemia

open access: yesCase Reports in Neurology, 2017
Acute cerebellar syndrome can be caused by high doses of cytarabine, but it has not been described in patients with acute lymphoblastic leukemia (ALL) who received hyper-CVAD chemotherapy.
Phu Ngoc Tran, Xiao-Tang Kong
doaj   +1 more source

Treatment of acute erythroleukaemia with high‐dose cytarabine in a cat with feline leukaemia virus infection

open access: yesVeterinary Medicine and Science, 2022
Erythroleukaemia is a malignant neoplasm of the erythroid lineage that rarely occurs in cats. It is associated with the feline leukaemia virus (FeLV), and owing to the poor prognosis, treatment is rarely reported.
Da Sol Park   +3 more
doaj   +1 more source

Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and although many patients respond to induction therapy, those who relapse or have refractory disease face a poor prognosis. Venetoclax has promising preclinical and clinical activity in ALL.
Andrew E. Place   +21 more
wiley   +1 more source

Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling

open access: yesCell Communication and Signaling, 2019
BackgroundTreatment of acute leukemia is challenging and long-lasting remissions are difficult to induce. Innovative therapy approaches aim to complement standard chemotherapy to improve drug efficacy and decrease toxicity.
Theresa Lowinus   +10 more
semanticscholar   +1 more source

Current Treatment Strategies and Supportive Care Practices in the Care of Children and Adolescents With Mature B‐Cell Non‐Hodgkin Lymphoma: A Survey of Children's Oncology Group Institutions

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Treatment strategies of mature B‐cell non‐Hodgkin lymphoma (B‐NHL) have been investigated in cooperative group settings to balance toxicity and cure. A survey of institutions participating in the Children's Oncology Group (COG) was completed to assess current practice patterns for treatment strategies, supportive care, imaging, and potential ...
Jennifer A. Belsky   +2 more
wiley   +1 more source

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

open access: yesNew England Journal of Medicine, 2003
BACKGROUND In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy.
T. Hughes   +10 more
semanticscholar   +1 more source

Reproductive adverse events in patients with non‐Hodgkin lymphoma treated with chemotherapeutic regimens including cyclophosphamide, doxorubicin, vincristine, prednisone or CHOP with rituximab: A systematic review and meta‐analysis

open access: yesPediatric Discovery, EarlyView.
The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R‐CHOP) is the first‐line treatment for non‐Hodgkin lymphoma (NHL). Nine articles involving 331 patients were included in the meta‐analysis, the pooled proportion of reproductive adverse events was 22.3% (95% CI 11.4%–33.2%; p < 0.001). The findings
Rong Han   +6 more
wiley   +1 more source

SAMHD1 is a barrier to antimetabolite-based cancer therapies

open access: yesMolecular & Cellular Oncology, 2017
The outcome of acute myelogenous leukemia (AML) therapy depends on the propensity of leukemic blasts to accumulate ara-CTP, the active triphosphate of cytarabine (ara-C). We identified sterile α motif and HD domain-containing protein 1 (SAMHD1) as an ara-
Sean G. Rudd   +2 more
doaj   +1 more source

Exploring 2D Graphene‐Based Nanomaterials for Biomedical Applications: A Theoretical Modeling Perspective

open access: yesSmall Science, EarlyView.
Two‐dimensional graphene‐based nanomaterials are of significant interest in biomedical applications due to their unique physicochemical properties. Computational modeling provides useful insights into their structure and interactions with biological systems, aiding the nanoparticle design.
Alexa Kamboukos   +2 more
wiley   +1 more source

Time to progression of mantle cell lymphoma after high‐dose cytarabine‐based regimens defines patients risk for death

open access: yesBritish Journal of Haematology, 2018
The current standard treatment of younger patients with mantle cell lymphoma (MCL) includes rituximab and highdose cytarabine (HD-AraC), usually followed by autologous stem cell transplantation (ASCT).
C. Visco   +34 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy